Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.75 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.75 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | MELK | Q14680 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24030796 | 0.88 | HDAC1 (0.77) | HDAC1HDAC6HDAC8HDAC11MELK | |
| SCHEMBL24247594 | 0.88 | TP53 (0.65) | HDAC1HDAC6HDAC8HDAC11TP53 | |
| SCHEMBL24031066 | 0.88 | HDAC1 (0.69) | HDAC1HDAC6HDAC8HDAC11MELK | |
| SCHEMBL24031070 | 0.87 | HDAC1 (0.74) | HDAC1HDAC6HDAC8HDAC11MELK | |
| SCHEMBL24030795 | 0.86 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC11MELK | |
| SCHEMBL24031017 | 0.85 | TP53 (0.62) | HDAC1HDAC6HDAC8HDAC11TP53 | |
| SCHEMBL30317688 | 0.85 | TP53 (0.62) | HDAC1HDAC6HDAC8HDAC11TP53 | |
| SCHEMBL24031154 | 0.85 | HDAC6 (0.67) | HDAC1HDAC6HDAC8HDAC11MELK | |
| SCHEMBL24031088 | 0.84 | HDAC1 (0.70) | HDAC1HDAC6HDAC8HDAC11TP53 | |
| SCHEMBL24031046 | 0.81 | HDAC1 (0.67) | HDAC1HDAC6HDAC8HDAC11MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110621317-A | Histone Deacetylase (HDACS) inhibitors | 安基生技新药股份有限公司 | 2019-12-27 | — | — | CN | claimed |
| CN-110621317-B | Inhibitors of Histone Deacetylase (HDACS) | 安基生技新药股份有限公司 | 2023-05-12 | — | — | CN | disclosed |
| US-11535598-B2 | Histone deacetylases (HDACs) inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2022-12-27 | — | — | US | disclosed |
| US-11535598-B2 | Histone deacetylases (HDACs) inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2022-12-27 | — | — | US | disclosed |
| EP-3624804-B1 | HISTONE DEACETYLASES (HDACS) INHIBITORS | ANNJI PHARM CO LTD (TW) | 2022-02-16 | — | — | EP | disclosed |
| EP-3624804-B1 | HISTONE DEACETYLASES (HDACS) INHIBITORS | ANNJI PHARM CO LTD (TW) | 2022-02-16 | — | — | EP | disclosed |
| US-20210355089-A1 | HISTONE DEACETYLASES (HDACS) INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2021-11-18 | — | — | US | disclosed |
| CN-110621317-A | Histone Deacetylase (HDACS) inhibitors | 安基生技新药股份有限公司 | 2019-12-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535598-B2 | Histone deacetylases (HDACs) inhibitors | HDAC1, HDAC3, HDAC2 | HDAC1 1/4885HDAC6 11/4885HDAC8 6/4885 |
| US-20210355089-A1 | HISTONE DEACETYLASES (HDACS) INHIBITORS | HDAC1, HDAC3, HDAC2 | HDAC1 1/4885HDAC6 8/4885HDAC8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.